RFK Jr. reshapes FDA peptide panel as scientists warn on unproven drugs
TL;DR Summary
Kennedy has packed the FDA’s Pharmacy Compounding Advisory Committee with peptide advocates and industry ties, even as FDA scientists warn that several popular injectable peptides lack proven safety or efficacy. The agency added nine new members (raising the panel to 13) who will review seven peptides and consider whether compounding pharmacies can produce them for human use, with final determinations expected after input from the advisory process.
- RFK Jr. stacks FDA panel with peptide peddlers as FDA scientists oppose access Ars Technica
- FDA scientists flag concerns with peptides, the trendy molecules RFK Jr. supports NPR
- FDA staff question peptides backed by Kennedy ahead of advisory panel review Reuters
- FDA panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr. PBS
- Longevity, wellness physicians named to panel advising FDA on peptides statnews.com
Reading Insights
Total Reads
1
Unique Readers
26
Time Saved
5 min
vs 6 min read
Condensed
94%
1,085 → 67 words
Want the full story? Read the original article
Read on Ars Technica